C]AZ10419369 in selected serotonergic projection areas and in the raphe nuclei (RN) were determined using the simplified reference tissue model, and for comparison also using a wavelet-aided parametric imaging approach. The BP ND values obtained from the first and second PET scans were compared by means of descriptive statistics, difference, absolute variability and intraclass correlation coefficient. Results Similar BP ND values were obtained with the two methods. The absolute mean differences in BP ND between PET 1 and PET 2 were less than 3 % in all serotonergic projection regions. Absolute variabilities were low in cortical regions (5 -7 %), low to moderate (7 -14 %) in subcortical regions, but higher (20 %) in the RN. Conclusion The BP ND of [ 11 C]AZ10419369 is highly reproducible in cortical regions and satisfactory in subcortical projection areas. The variability in the RN is higher. Thus larger sample sizes or larger divergences are required to assess a potential difference between subjects or between experimental conditions in this region.
AZ10419369 is a recently developed radioligand that binds selectively to the serotonergic 5-HT 1B receptor. This serotonin receptor subtype functions both as an autoreceptor and as a heteroreceptor, controlling the release of other neurotransmitters. Thus, it has been suggested that the 5-HT 1B receptor governs the regulation of a variety of physiological functions including locomotion, thermoregulation, feeding behaviour, sleep, aggression and impulsivity. This receptor is also of interest in psychiatric and somatic disorders such as anxiety, obsessive compulsive disorder, depression, migraine (for reviews see Sari [1] and Ruf and Bhagwagar [2] ) and Parkinson's disease [3] . As an example of the use of [ 11 C] AZ10419369 in relation to the treatment of CNS disorders, in a recent study the antimigraine drug zolmitriptan was shown to occupy 5-HT 1B receptors in human subjects [4] . The central serotonergic system originates from the raphe nuclei (RN) and projects to almost all brain regions. In the human brain, the 5-HT 1B receptor is expressed in, among other regions, the cerebral cortex, the striatum, the thalamus and the RN [5, 6] . The 5-HT 1B receptor in the RN might be of special interest, as it has been shown to participate in the regulation of serotonergic firing and release [7] .
The PET radioligand [ 11 C]AZ10419369 has been examined in both nonhuman primates and human subjects, and confirmed to be suitable for labelling the 5-HT 1B receptors in vivo [8] [9] [10] . Importantly, [ 11 C]AZ10419369 is the first radioligand demonstrated to be sensitive to changes in endogenous serotonin concentrations [11, 12] . Consequently, there is now an opportunity for a series of clinical studies on the pathophysiology and pharmacological treatment of serotoninrelated disorders. To measure changes in endogenous serotonin concentrations, typically two consecutive PET measurements in the same subject are obtained-one measurement at baseline and one after a serotonergic challenge. A challengeinduced change in serotonin concentration would be expected to cause an observable change in the binding potential of the radioligand. In initial studies with [ 11 C]AZ10419369 in the monkey, the serotonin-enhancing compound (±)-fenfluramine has been used to elevate endogenous serotonin concentrations [11, 13] . However, changes in serotonin concentrations induced by other medical drugs or changes related to disease might be less pronounced than the strong effect evoked by (±)-fenfluramine (i.e. up to 50 % average reduction in binding potential). For example, a single clinically relevant dose of the antidepressant drug escitalopram has recently been shown to increase the binding potential of [
11 C]AZ10419369 by approximately 5 % in serotonergic projection areas [12] . To estimate sample size in future clinical studies and as an aid in the evaluation of such studies, an initial step is to understand the test-retest variability of [ 
Materials and methods

Study design
The study was conducted at Karolinska University Hospital, Solna, Sweden, and was approved by the local ethics and Radiation Safety Committees and the Medical Products Agency in Sweden. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Eight subjects were examined twice on the same day with PET and [ 
Study subjects
All subjects gave verbal and written consent before any studyspecific procedures were started. Eight men (age 21 -28 years) were recruited from a list of subjects who had previously expressed an interest in participating in clinical PET studies. All subjects were healthy according to medical history and physical examination, including ECG, routine blood tests and MRI of the brain. Psychopathology was assessed using a structured questionnaire for screening of psychiatric diseases (the Mini-International Neuropsychiatric Interview) [14] . A negative urine drug screen was required at the screening visit and on the PET measurement day. No regular use of medications that could interfere with the serotonin system was allowed, as well as past or present use of antidepressant or antipsychotic drugs.
PET measurements
Each subject participated in two PET measurements performed on the same day, with approximately 4 h between. As sleep might affect serotonin concentrations [15] , wakefulness was controlled for and recorded every 5 min throughout the PET measurements. PET examinations were performed using the HRRT (Siemens Molecular Imaging, Knoxville, TN). The HRRT system used had been demonstrated in a previous phantom study to have a spatial resolution of approximately 1.5-mm full-width half-maximum, when the image reconstruction included modelling of the point spread function [16] . A plastic helmet made individually for each subject was used during each PET examination in order to minimize head movements and to ensure maintenance of the same head position in all experiments.
[ 11 C]AZ10419369 was prepared by N-methylation of the corresponding desmethyl precursor using [ 11 C]methyl triflate as described previously [9] . At each examination, a saline solution containing [ 11 C]AZ10419369 with a radioactivity of 374 -429 MBq (410±15 MBq, mean±SD) was injected into the antecubital vein as a bolus over 2 s. The specific radioactivity at the time of injection exceeded 265 GBq/μmol and the injected radioligand mass was <1 μg on all occasions. Radioactivity in the brain was measured in list mode fashion over 63 min. The radioactivity from each PET measurement was reconstructed in a series of time frames consisting of eight 10-s, five 20-s, four 30-s, four 1-min, four 3-min and seven 6-min frames.
Regions of interest T1-weighted MR images were acquired in each subject using a Discovery 750 3-T MR system (GE Medical Systems, Milwaukee, WI). The MR images were realigned so that the anterior-posterior commissure plane was placed horizontally. Regions of interest (ROIs) were manually delineated on the realigned MR images for each subject by means of Human Brain Atlas software. The following ROIs were depicted: the frontal cortex, the temporal cortex, the occipital cortex, the putamen, the thalamus and the cerebellar cortex. In addition, a ROI in the dorsal brainstem was defined for inclusion of the rostral parts of the RN. PET data were corrected for movement, using frame-by-frame motion correction as previously described [17] . MR images were then coregistered to averaged PET images using the Statistical Parametric Mapping software (SPM5; Wellcome Department of Cognitive Neuroscience, London, UK). ROIs were transferred to the dynamic PET images to generate time-activity curves.
Determination of binding potential
The binding potential of [ 11 C]AZ10419369 in each region was determined using the simplified reference tissue model (SRTM). The SRTM method has previously been validated for quantification of [ 11 C]AZ10419369 binding in the human brain [8] . The cerebellar cortex has previously been found to contain negligible levels of 5-HT 1B receptors [5, 18] and was therefore regarded as a suitable region for the estimation of free and nonspecifically bound radioligand. The binding potential in this study refers to BP ND , i.e. the ratio of specifically bound radioligand to that of nondisplaceable radioligand in tissue under equilibrium conditions [19] .
Parametric imaging
For comparison, the BP ND for each region was also quantified using the wavelet-aided parametric imaging (WAPI) approach [20] . A description of the WAPI method and the results of this analysis are given in the Supplementary material.
Statistics
The BP ND in each ROI of PET 1 and PET 2 was compared by means of descriptive statistics including mean, standard deviation (SD), coefficient of variance (CV), difference (%), variability (%) and intraclass correlation coefficient (ICC). The difference, D, was expressed as the difference in BP ND between PET 1 and PET 2, relative to the BP ND from PET 1:
⋅100
The variability, Var, was expressed as the difference in BP ND between PET 1 and that from PET 2, relative to the mean of the two values:
The ICC was calculated according to the following equation:
This is a one-way ICC, where MS BS denotes the betweensubject mean square, MS WS the within-subject mean square and n the number of measurements (i.e. 2) [21, 22] .
A two-tailed paired t-test was used to compare the injected radioactivity and the mass of [ 11 C]AZ10419369 injected during the first and second PET scan. The statistical analysis was performed using SAS statistical software JMP 10 (SAS Institute, Cary, NC). The ICC was calculated using SPSS version 20.
Results
All eight subjects underwent two PET scans according to the protocol. The second PET scan started on average 4 h and 5 min after initiation of the first PET scan (SD 15 min, range 3 h 48 min to 4 h 40 min). There was no statistically significant difference in the mean radioactivity or the mean mass of Table 1 .
Difference in BP ND between PET 1 and PET 2
The absolute mean differences in BP ND between PET 1 and PET 2 were less than 3 % in all regions except the RN. The absolute variabilities were low (5 -7 %) in cortical regions and low to moderate (7 -14 %) in subcortical projection areas, but higher (20 %) in the RN. The variabilities and differences in BP ND between PET 1 and PET 2 are given in Table 1 and illustrated in Fig. 2 .
Similar BP ND values were obtained from PET 1 and PET 2 in the projection areas (Fig. 3) .
Intraclass correlation coefficient
The ICC was highest in the occipital cortex (0.80). The ICCs in the frontal and temporal cortices were substantially lower (0.32 and 0.37, respectively). The ICCs for the subcortical projection areas were 0.44 and 0.61, respectively. The ICCs for each region are given in Table 1 .
Discussion
In this PET study, we examined the test-retest reliability of [ [25] . On the contrary, the variability in the region defined for the RN was higher (around 20 %). The volume of the ROI defined for the RN is small (1.9±0.3 mL), and therefore the signal-to-noise ratio is lower than in larger regions with the same receptor density. Additionally, it is not possible to delineate the exact anatomical boundaries of the RN on MRI images. Thus, the region defined for the RN likely also includes some of the surrounding tissue, which will "dilute" the radioactivity signal. These conditions increase the noise and might explain the higher variability in BP ND in this particular region.
Our research group has recently used [ 11 C]AZ10419369 to investigate the effect of the antidepressant drug escitalopram on endogenous serotonin concentrations in the human brain [12] . The BP ND of [ 11 C]AZ10419369 increased in all serotonergic projection areas after drug administration (indicating decreased serotonin concentrations), but there was on the contrary a trend to a decrease in BP ND in the RN. While the results of the present study support the interpretation that escitalopram indeed induced a difference in BP ND in the serotonergic projection areas, the large variability found in the RN could serve as an explanation for why it was difficult to obtain conclusive evidence for an effect of escitalopram in this region.
In addition to the variability, the ICC is a common metric used to assess test-retest reliability. However, there is no consensus regarding the value required to confirm "good reliability". There are several versions of ICC, each representing different situations and underlying assumptions [22] . As we did not expect any systematic difference in the ICCs between PET 1 and PET 2, a one-way BP ND was used in the current study. The ICC can be viewed as the proportion of a variance that can be attributed to differences between subjects (i.e. the between-subject variance divided by the total variance, including the variance between measurements). A higher ICC indicates that the difference between two measurements depends more on the variance among subjects than on the variance due to the actual measurements, and a lower ICC indicates that differences are mostly due to measurement variability. Thus, the ICC depends not only on the variability between two measurements, but also on the variability among subjects. Even if the measurement variability is kept constant, a lower ICC value will be achieved if there is a lower variability between subjects. In the present study, the ICC value for the frontal and temporal cortices was low, even though the absolute variability in BP ND between the two PET scans was as low as 5 -7 %. This can be explained by the low CV for the BP ND in these regions, indicating a low between-subject variance. Thus, despite the low ICC values, it cannot be excluded that the test-retest reliability is also high in these regions.
A limitation of the present study was that only healthy men between 20 and 30 years of age were included. Previous studies have indicated that hormonal fluctuations during the menstrual cycle in women might affect the serotonin system [26] . While it is unlikely that these fluctuations would be highly pronounced during the course of a few hours, they could possibly lead to differences in the BP ND of [ 11 C] AZ10419369 if a longer time (i.e. days or weeks) is used between two PET scans. However, such changes would be The serotonin system has been implicated in a variety of psychiatric disorders, and drugs targeting the serotonin transporter are commonly used to treat depression and anxiety. Yet the pathophysiology underlying these conditions is not fully understood. Providing an opportunity for noninvasive studies of the human brain in vivo, the PET technique is a powerful tool for clinical examinations of the serotonergic system in relation to psychiatric pathology and treatment. Several radioligands have been developed to target the serotonergic transporter as well as several of the serotonergic receptor subtypes [27] . However, methods for measurement of endogenous serotonin concentrations have previously been lacking. Thus, because of their sensitivity to changes in endogenous serotonin concentrations, [ The use of parametric imaging for analysis of PET measurements has recently increased. For comparative reasons, 
Conclusion
The BP ND of [ 11 C]AZ10419369 is highly reproducible in cortical regions and satisfactory in the subcortical projection areas measured. The variability in the RN is higher, and thus larger sample sizes or larger divergences are required to assess a potential difference between subjects or between measurements in this region. 
